Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Unexo Life Sciences Private Limited
483
•Unexo Life Sciences Private Limited•May 14, 2024

Unexo Life Sciences Private Limited – FDA 483, May 14, 2024

Record Details

During an FDA inspection from May 1 to May 14, 2024, Unexo Life Sciences, Private Limited, an Over-The-Counter (OTC) drug manufacturer in New Delhi, India, was cited for significant violations of Good Manufacturing Practices (GMP). The observations highlight critical failures across quality systems, laboratory controls, facilities, equipment, production, and packaging. Key issues included a severely compromised quality system, where the Quality Control Unit failed to ensure data accuracy and integrity. Investigators found missing, incomplete, or intentionally fabricated batch records, and inadequate control over computerized systems. The company's Managing Director reportedly admitted to not having complete batch records and creating some on request.

Investigations into product discrepancies and adverse events were inadequate, lacking root cause analysis or corrective actions. Laboratory operations failed to validate test methods for US-marketed products, and crucial raw data and Certificates of Analysis were missing or deliberately erased from computers. Facility and equipment issues included unclean product-contact surfaces, faulty gauges, unreviewed alarms, and the use of unqualified equipment for US product manufacturing. Furthermore, essential controls for packaging and labeling were absent or not followed, leading to uncontrolled access to labeling materials and finished products lacking proper identification and manufacturing history. Unexo Life Sciences is expected to promptly address these observations through comprehensive corrective and preventive actions to ensure the safety, quality, and efficacy of its drug products.

Company
Unexo Life Sciences Private Limited
Inspection date
May 14, 2024
Product type
drugs
Office
Foreign - CDER (Non-Bioresearch Monitoring)
People
  • Shelby N. Turner
  • Nicole E. Knowlton (Investigator )
  • Kellia N. Hicks (Investigator)
View Company Profile

ID · 7a0a82d3-ad77-47eb-94ff-f23eaa9c7806

Other documents for Unexo Life Sciences Private Limited
  • WARNING_LETTER - 2024-05-14May 14, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Unexo Life Sciences Private Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.